|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
61,413,000 |
Market
Cap: |
8.95(B) |
Last
Volume: |
591,041 |
Avg
Vol: |
504,733 |
52
Week Range: |
$114.17 - $208.42 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Repligen is a life sciences company that develops and commercializes bioprocessing technologies and systems used in the process of manufacturing biological drugs. Co.'s bioprocessing business is comprised of:Filtration, which includes XCell Alternating Tangential Flow systems that are used in upstream perfusion cell culture processing; Chromatography, which includes products used in downstream purification, development, manufacturing and quality control of biological drugs; Process Analytics, which complements and supports its Filtration, Chromatography and Proteins franchises; and Proteins, which are represented by its Protein A affinity ligands and cell culture growth factor products.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
1,500 |
Total Buy Value |
$0 |
$0 |
$0 |
$238,260 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
3 |
Total Shares Sold |
23,589 |
45,669 |
50,307 |
151,828 |
Total Sell Value |
$4,058,631 |
$8,416,817 |
$9,119,818 |
$30,980,273 |
Total People Sold |
2 |
4 |
5 |
6 |
Total Sell Transactions |
2 |
5 |
7 |
17 |
End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Barthelemy Nicholas |
Director |
|
2020-11-09 |
4 |
S |
$195.51 |
$237,349 |
D/D |
(1,214) |
1,450 |
|
-8% |
|
Hunt Anthony |
Chief Executive Officer |
|
2020-09-10 |
4 |
AS |
$146.85 |
$6,721,018 |
D/D |
(45,351) |
233,327 |
|
50% |
|
Hunt Anthony |
Chief Executive Officer |
|
2020-09-10 |
4 |
OE |
$26.05 |
$1,181,394 |
D/D |
45,351 |
278,678 |
|
- |
|
Kuriyel Ralf |
Senior VP, R&D |
|
2020-08-06 |
4 |
S |
$153.79 |
$768,950 |
D/D |
(5,000) |
26,089 |
|
-23% |
|
Kuriyel Ralf |
Senior VP, R&D |
|
2020-08-06 |
4 |
OE |
$33.87 |
$169,350 |
D/D |
5,000 |
31,089 |
|
- |
|
Ryan Thomas F Jr |
Director |
|
2020-07-31 |
4 |
S |
$151.77 |
$470,129 |
D/D |
(3,095) |
1,464 |
|
-20% |
|
Ryan Thomas F Jr |
Director |
|
2020-07-31 |
4 |
OE |
$67.71 |
$142,800 |
D/D |
2,109 |
4,559 |
|
- |
|
Dawes Karen A |
Director |
|
2020-06-18 |
4 |
AS |
$113.58 |
$2,154,851 |
D/D |
(18,705) |
100,734 |
|
51% |
|
Hunt Anthony |
Chief Executive Officer |
|
2020-05-21 |
4 |
OE |
$16.55 |
$1,206,140 |
D/D |
50,039 |
233,327 |
|
- |
|
Hunt Anthony |
Chief Executive Officer |
|
2020-05-21 |
4 |
AS |
$139.17 |
$6,562,409 |
D/D |
(46,953) |
230,241 |
|
6% |
|
Dawes Karen A |
Director |
|
2020-05-20 |
4 |
AS |
$135.91 |
$72,093 |
D/D |
(517) |
119,439 |
|
8% |
|
Barthelemy Nicholas |
Director |
|
2020-05-18 |
4 |
S |
$142.53 |
$428,873 |
D/D |
(3,009) |
2,664 |
|
-15% |
|
Barthelemy Nicholas |
Director |
|
2020-05-18 |
4 |
OE |
$67.71 |
$142,800 |
D/D |
2,109 |
5,673 |
|
- |
|
Dawes Karen A |
Director |
|
2020-05-18 |
4 |
AS |
$135.76 |
$220,448 |
D/D |
(1,600) |
119,956 |
|
15% |
|
Kuriyel Ralf |
Senior VP, R&D |
|
2020-05-15 |
4 |
S |
$140.69 |
$61,200 |
D/D |
(435) |
26,089 |
|
-13% |
|
Snodgres Jon |
Chief Financial Officer |
|
2020-05-15 |
4 |
S |
$140.43 |
$92,684 |
D/D |
(660) |
32,267 |
|
-13% |
|
Muir Glenn P |
Director |
|
2020-05-13 |
4 |
A |
$0.00 |
$0 |
D/D |
527 |
5,905 |
|
- |
|
Barthelemy Nicholas |
Director |
|
2020-05-13 |
4 |
A |
$0.00 |
$0 |
D/D |
527 |
3,564 |
|
- |
|
Dawes Karen A |
Director |
|
2020-05-13 |
4 |
A |
$0.00 |
$0 |
D/D |
722 |
121,556 |
|
- |
|
Ryan Thomas F Jr |
Director |
|
2020-05-13 |
4 |
A |
$0.00 |
$0 |
D/D |
527 |
2,450 |
|
- |
|
Kuriyel Ralf |
Senior VP, R&D |
|
2020-05-13 |
4 |
S |
$126.88 |
$1,022,373 |
D/D |
(8,000) |
26,524 |
|
-11% |
|
Kuriyel Ralf |
Senior VP, R&D |
|
2020-05-13 |
4 |
OE |
$33.05 |
$266,040 |
D/D |
8,000 |
34,524 |
|
- |
|
Snodgres Jon |
Chief Financial Officer |
|
2020-05-13 |
4 |
S |
$126.77 |
$1,981,875 |
D/D |
(15,394) |
32,927 |
|
-11% |
|
Snodgres Jon |
Chief Financial Officer |
|
2020-05-13 |
4 |
OE |
$26.05 |
$374,956 |
D/D |
12,194 |
48,321 |
|
- |
|
Barthelemy Nicholas |
Director |
|
2020-04-22 |
4 |
AS |
$109.99 |
$295,653 |
D/D |
(2,688) |
3,037 |
|
38% |
|
647 Records found
|
|
Page 10 of 26 |
|
|